{"meta":{"status":200,"messages":[],"pagination":{"max":1,"offset":0,"count":1,"total":1,"pageNum":1,"totalPages":1,"sort":null,"currentUrl":"https://api.digitalmedia.hhs.gov/api/v2/resources/media.json?offset=0&max=1&ignoreHiddenMedia=1&format=json&id=18447","nextUrl":null,"previousUrl":null}},"results":[{"content":"
\nThe NCI and VA Interagency Group to Accelerate Trials Enrollment (NAVIGATE) program is a partnership between the National Cancer Institute (NCI) and the Department of Veterans Affair (VA) to facilitate enrollment of veterans with cancer into NCI-funded clinical trials.
\nVeterans can play an important role in their own care and the health of future generations by joining a cancer clinical trial. Through NAVIGATE, veterans will get easier access to promising new cancer treatments, including precision medicine and immunotherapies, through participating in NCI-supported cancer clinical trials.
\nThis agreement between NCI and the VA will increase the number of VA Medical Centers participating in and conducting NCI-supported cancer clinical trials. The program is expected to enhance accrual to trials carried out through the National Clinical Trials Network (NCTN) and the NCI Community Oncology Research Program (NCORP), resulting in more timely trial completion while advancing the health of veterans with cancer.
\nThe VA has long recognized its responsibility to participate in national efforts to lessen the burden of cancer for veterans and their families.
\nVA manages a robust clinical research program that includes clinical trials in cancer and other diseases at more than 100 sites nationwide. However, VA facilities often face challenges initiating and completing trials.
\nThe NAVIGATE program aims to address these challenges and to make it easier for veterans to access state-of-the-art treatments via clinical trials by bringing the NCI trials to them, so they do not have to seek treatment outside of the VA.
\nNAVIGATE is an opportunity for government agencies long committed to veterans\u2019 health to partner at the national level to make clinical trials more accessible. The initial focus of this collaboration is on activities to facilitate participation of VA facilities in NCI trials, and the overall focus is to explore ways to sustain VA Medical Center participation in NCI clinical trials beyond this agreement.
\nThe 3-year NAVIGATE program is expected to build the capacity of participating VA Medical Centers to offer NCI clinical trials in the future.
\nThe program aims to accelerate the VA Cooperative Studies Program's progress in adopting a centralized approach to address site-level challenges to more efficiently recruit patients to national trials.
\nNAVIGATE will increase participation of VA clinical investigators in clinical research and help identify studies that may be of particular importance to veterans with cancer while enhancing the VA\u2019s overall leadership role in cancer care and clinical research.
\nLocation | \nFacility Name | \nPrincipal Investigator(s) | \n
---|---|---|
Atlanta, GA | \nAtlanta VA Health Care System | \nWayne Harris, M.D. | \n
Bronx, NY | \nJames J. Peters VA Medical Center | \nSusan Bates, M.D. | \n
Charleston, SC | \nRalph H. Johnson VA Medical Center | \nStephen Savage, M.D. and Oleksandra Lupak, M.D. | \n
Denver, CO | \nVA Eastern Colorado Health Care System | \nDaniel Bowles, M.D. | \n
Durham, NC | \nDurham VA Medical Center | \nDaphne Friedman, M.D. | \n
Hines, IL | \nEdward Hines Jr VA Hospital | \nCheryl Czerlanis, M.D. | \n
Long Beach, CA | \nTibor Rubin VA Medical Center | \nPankaj Gupta, M.D. and Homayoon Sanati, M.D. | \n
Minneapolis, MN | \nMinneapolis VA Health Care System | \nSharon Luikart, M.D. and Mark Klein, M.D. | \n
Palo Alto, CA | \nVA Palo Alto Health Care System | \nHarlan Pinto, M.D. | \n
Portland, OR | \nPortland VA Medical Center | \nMark Garzotto, M.D. | \n
San Antonio, TX | \nAudie L. Murphy VA Hospital / South Texas Veterans Health Care System | \nMichael Liss, M.D. and Paromita Datta, M.D. | \n
West Haven, CT | \nVA Connecticut Healthcare System | \nHerta Chao, M.D., Ph.D. | \n
Posted:
\nUpdated:
\nReviewed:
\n